Vanguard Group Inc. Has $222.41 Million Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Vanguard Group Inc. increased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 0.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,150,759 shares of the specialty pharmaceutical company's stock after acquiring an additional 22,852 shares during the period. Vanguard Group Inc. owned about 11.14% of Supernus Pharmaceuticals worth $222,411,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. Barclays PLC raised its stake in shares of Supernus Pharmaceuticals by 88.3% during the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock worth $3,393,000 after purchasing an additional 51,005 shares in the last quarter. Geode Capital Management LLC increased its holdings in Supernus Pharmaceuticals by 5.3% in the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company's stock worth $46,218,000 after buying an additional 74,438 shares during the last quarter. Franklin Resources Inc. raised its position in Supernus Pharmaceuticals by 7.6% during the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company's stock valued at $987,000 after acquiring an additional 2,121 shares in the last quarter. Empowered Funds LLC bought a new stake in Supernus Pharmaceuticals in the fourth quarter worth approximately $1,498,000. Finally, Smartleaf Asset Management LLC increased its stake in shares of Supernus Pharmaceuticals by 219.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after purchasing an additional 870 shares during the last quarter.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the sale, the vice president now owns 10,149 shares of the company's stock, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Jonathan Rubin sold 927 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company's stock, valued at $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,104 shares of company stock valued at $440,263 in the last quarter. Insiders own 9.30% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. StockNews.com lowered shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Wednesday. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock traded down $0.69 on Thursday, reaching $31.07. The stock had a trading volume of 457,254 shares, compared to its average volume of 492,225. The business's 50-day moving average price is $33.69 and its two-hundred day moving average price is $35.03. The stock has a market cap of $1.73 billion, a P/E ratio of 29.04 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.